Earlier this full month, the company reached agreement with the United States Food and Medication Administration , under the Special Protocol Evaluation process, on the design of its planned Phase 3 research. The trial is the initial prospectively designed superiority research to be executed in CABP, a precedent-setting medical trial style for oral antibiotics that the company believes will make a substantial contribution to the field of CABP and antimicrobial medical trial design. Advanced Lifestyle Sciences CEO, Dr. Michael T. Flavin, said: Provided Restanza’s demonstrated effectiveness as a wide biodefense countermeasure against such bioterror brokers as anthrax, tularemia and plague, in addition to its value as a potential treatment for community obtained bacterial pneumonia, we intend to pursue all opportunities to expand our romantic relationship with the US government and seek additional funding that may help complete advancement of Restanza, support regulatory filings and gain FDA acceptance.In the placebo group, 53 percent of participants acquired at least one recurrence through the 3-yr trial. Low-dosage prophylactic penicillin given for a period of 12 months nearly halved the risk of recurrence during the intervention period, and sufferers who received prophylaxis experienced considerably fewer recurrent episodes over the 3-yr period than those that received placebo. Even though some level of protection appeared to be sustained for many months after the final end of prophylactic therapy, this impact was lost by thirty six months, a finding that suggests that longer-term prophylaxis may be required.